贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理

Core Viewpoint - The company, Betta Pharmaceuticals (300558.SZ), has received acceptance from the National Medical Products Administration (NMPA) for its application for the marketing authorization of Ensartinib capsules (brand name: Beimei Na) for postoperative adjuvant therapy in patients with ALK-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have previously undergone surgical resection and have a physician's decision on adjuvant chemotherapy [1] Group 1 - The NMPA issued an acceptance notice for the company's application [1] - The application is for Ensartinib capsules intended for specific NSCLC patients [1] - The targeted patient population includes those who have undergone surgical treatment and are ALK-positive [1]